Analyst stock forecast
enGene Therapeutics Forecast: $3.29 Analyst Target
Direct answer
enGene Therapeutics's average price target is $3.29.
The target implies +71.1% from the recorded current price, and the consensus rating is Hold.
The low target implies +4.2%, the high target implies +160.4%, and the range spans 156.3% of the current price.
Forecast evidence checked September 25, 2026.
Get free enGene Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.92
- Average price target
- $3.29
- High price target
- $5.00
- Low price target
- $2.00
- Low target gap
- +4.2%
- Target upside
- +71.1%
- High target gap
- +160.4%
- Target range width
- 156.3%
- Consensus rating
- Hold
- Analysts
- 7
- Evidence date
- September 25, 2026
- Valid through
- October 2, 2026
Explore related company data
Read the frequently asked questions.
What is enGene Therapeutics's average price target?
enGene Therapeutics's verified average price target is $3.29. The target range is $2.00 to $5.00.
How far are enGene Therapeutics's low and high targets from the recorded price?
The low target implies +4.2%, while the high target implies +160.4%.
How many analysts are included in enGene Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is enGene Therapeutics's target upside or downside calculated?
The average target of $3.29 is divided by the recorded price of $1.92, then one is subtracted to produce +71.1%. This does not guarantee a future return.
When was enGene Therapeutics's analyst forecast verified?
The data was verified on 2026-09-25. The dataset is valid through 2026-10-02.